Top Pulmonary Arterial Hypertension Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Pulmonary Arterial Hypertension Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Pulmonary Arterial Hypertension industry players.

Pulmonary Arterial Hypertension Market Competitive Landscape

The market for pulmonary arterial hypertension is dominated by a small number of companies in terms of branded or patented medications. Gilead Sciences, Johnson & Johnson, United Therapeutics, and other companies are among them. To counter this, numerous pharmaceutical firms are launching generic versions of pulmonary arterial hypertension medications in an effort to enter the PAH market as a result of the increased number of patent expirations.

Pulmonary Arterial Hypertension Market Top Player’s Company Profiles

  • GlaxoSmithKline plc (United Kingdom)
  • Gilead Sciences, Inc. (United States)
  • Pfizer, Inc. (United States)
  • Arena Pharmaceuticals, Inc. (United States)
  • Reata Pharmaceuticals, Inc. (United States)
  • SteadyMed Therapeutics, Inc. (United States)
  • Lung Biotechnology PBC (United States)
  • AstraZeneca plc (United Kingdom)
  • Bristol-Myers Squibb Company (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Liquidia Technologies, Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Actelion Pharmaceuticals US, Inc. (United States)
  • Acceleron Pharma Inc. (United States)
  • Eli Lilly and Company (United States)
  • Bayer HealthCare Pharmaceuticals (United States)
  • Mallinckrodt Pharmaceuticals (United Kingdom)
  • Aadi Bioscience, Inc. (United States)
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Pulmonary Arterial Hypertension Market size was valued at USD 8.2 Billion in 2024 and is poised to grow from USD 8.63 Billion in 2025 to USD 13.05 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026–2033).

The market for pulmonary arterial hypertension is dominated by a small number of companies in terms of branded or patented medications. Gilead Sciences, Johnson & Johnson, United Therapeutics, and other companies are among them. To counter this, numerous pharmaceutical firms are launching generic versions of pulmonary arterial hypertension medications in an effort to enter the PAH market as a result of the increased number of patent expirations. 'United Therapeutics Corporation (United States) ', 'Bayer AG (Germany) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Gilead Sciences, Inc. (United States) ', 'Novartis International AG (Switzerland) ', 'Pfizer Inc. (United States) ', 'Merck & Co., Inc. (United States) ', 'Bristol-Myers Squibb Company (United States) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Viatris Inc. (United States) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Alembic Pharmaceuticals Ltd. (India) ', 'Aerami Therapeutics Holdings Inc. (United States) ', 'Asklepion Pharmaceuticals LLC (United States) ', 'Keros Therapeutics (United States) ', 'Liquidia Corporation (United States) ', 'Ferrer (Spain) ', 'Gossamer Bio (United States)'

A uncommon, progressive condition known as pulmonary arterial hypertension (PAH) is characterised by elevated blood pressure in the arteries that carry blood to the lungs. Globally, the prevalence of PAH is rising as a result of ageing populations, rising rates of risk factors like obesity, and improved diagnostic techniques. This is anticipated to increase demand for PAH remedies.

With advancements in technology and an improved understanding of the genetic basis of PAH, there is an increasing focus on developing personalized therapies for patients. Companies are investing in research and development to identify biomarkers that can be used to predict disease progression and response to treatment, and to develop therapies that target specific genetic mutations.

In 2022, North America held the biggest revenue share of over 40.0% in the market for pulmonary arterial hypertension. The sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments, are to blame for the significant portion. Additionally, heightened awareness, a high prevalence of diagnoses, and favorable government measures assist the expansion of the business in this area. The rise of the local market is aided by the presence of significant companies and a carefully thought-out reimbursement system. The demand for advanced healthcare facilities for treating pulmonary arterial hypertension in the region is being driven by the increased prevalence of chronic and infectious diseases and the high diagnostic rate

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Idiopathic Pulmonary Fibrosis Market
Buy Now GET FREE SAMPLE
Idiopathic Pulmonary Fibrosis Treatment Market
Buy Now GET FREE SAMPLE
Cardiovascular Drugs Market
Buy Now GET FREE SAMPLE
Inhaled Nitric Oxide Market
Buy Now GET FREE SAMPLE
Respiratory Disease Testing Market
Buy Now GET FREE SAMPLE
COPD and Asthma Devices Market
Buy Now GET FREE SAMPLE
Lung Cancer Market
Buy Now GET FREE SAMPLE
Hemodynamic Monitoring Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Pulmonary Arterial Hypertension Market
Pulmonary Arterial Hypertension Market

Report ID: SQMIG35H2222

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE